{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:14:31Z","timestamp":1780496071930,"version":"3.54.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.esmoop.2023.101206","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T17:32:07Z","timestamp":1684949527000},"page":"101206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for adjuvant radiotherapy in breast cancer"],"prefix":"10.1016","volume":"8","author":[{"given":"E.","family":"Sapir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.I.","family":"Cherny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.D.","family":"Ennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.B.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.W.","family":"Corn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.esmoop.2023.101206_bib1","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMp1011024","article-title":"What is value in health care?","volume":"363","author":"Porter","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.esmoop.2023.101206_bib2","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","article-title":"American society of clinical oncology statement: a conceptual framework to assess the value of cancer treatment options","volume":"33","author":"Schnipper","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.esmoop.2023.101206_bib3","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1200\/JCO.2016.68.2518","article-title":"Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received","volume":"34","author":"Schnipper","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2023.101206_bib4","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A\u00a0standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2023.101206_bib5","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-Magnitude of Clinical Benefit Scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101206_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100229","article-title":"Clinical benefit of systemic therapies for recurrent ovarian cancer-ESMO-MCBS scores","volume":"6","author":"Broekman","year":"2021","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.esmoop.2023.101206_bib7","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1093\/annonc\/mdx547","article-title":"Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO framework","volume":"28","author":"de Hosson","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101206_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000611","article-title":"EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies","volume":"5","author":"Kiesewetter","year":"2020","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.esmoop.2023.101206_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000681","article-title":"Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1","volume":"5","author":"Knapen","year":"2020","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.esmoop.2023.101206_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000743","article-title":"Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies","volume":"5","author":"Paluch-Shimon","year":"2020","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101206_bib11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/jamaoncol.2020.6139","article-title":"Drug-radiotherapy combinations in 2020 \u2013 a landmark year?","volume":"7","author":"Walker","year":"2021","journal-title":"JAMA Oncol"},{"issue":"26","key":"10.1016\/j.esmoop.2023.101206_bib12","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1200\/JCO.2014.55.1143","article-title":"Role of radiation therapy in palliative care of the patient with cancer","volume":"32","author":"Lutz","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101206_bib13","doi-asserted-by":"crossref","first-page":"pkab046","DOI":"10.1093\/jncics\/pkab046","article-title":"Moving forward in the next decade: radiation oncology sciences for patient-centered cancer care","volume":"5","author":"Coleman","year":"2021","journal-title":"JNCI Cancer Spectr"},{"issue":"7","key":"10.1016\/j.esmoop.2023.101206_bib14","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/1878-0261.12731","article-title":"What will radiation oncology look like in 2050? A look at a changing professional landscape in Europe and beyond","volume":"14","author":"Baumann","year":"2020","journal-title":"Mol Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101206_bib15","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ijrobp.2020.07.021","article-title":"Clinical trialism and the bedrock of hope","volume":"108","author":"Sapir","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.esmoop.2023.101206_bib16","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/S1470-2045(22)00548-4","article-title":"ASTRO calls for a new value-based reimbursement structure for radiotherapy","volume":"23","author":"Das","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101206_bib17","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S1470-2045(18)30917-3","article-title":"Towards an evidence-informed value scale for surgical and radiation oncology: a multi-stakeholder perspective","volume":"20","author":"Lievens","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101206_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(19)30174-3","article-title":"ESMO-MCBS: setting the record straight","volume":"20","author":"Cherny","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101206_bib19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.prro.2018.01.012","article-title":"Radiation therapy for the whole breast: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline","volume":"8","author":"Smith","year":"2018","journal-title":"Pract Radiat Oncol"},{"issue":"9804","key":"10.1016\/j.esmoop.2023.101206_bib20","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/S0140-6736(11)61629-2","article-title":"Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials","volume":"378","author":"Early Breast Cancer Trialists\u2019 Collaborative","year":"2011","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.esmoop.2023.101206_bib21","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","article-title":"The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","volume":"14","author":"Haviland","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101206_bib22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1470-2045(09)70382-1","article-title":"Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials","volume":"11","author":"Hopwood","year":"2010","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2023.101206_bib23","first-page":"CD003860","article-title":"Fraction size in radiation treatment for breast conservation in early breast cancer","volume":"7","author":"James","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.esmoop.2023.101206_bib24","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa0906260","article-title":"Long-term results of hypofractionated radiation therapy for breast cancer","volume":"362","author":"Whelan","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101206_bib25","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ijrobp.2021.10.005","article-title":"Hypofractionated radiation therapy for breast cancer: financial risk and expenditures in the United States, 2008 to 2017","volume":"112","author":"Saulsberry","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101206_bib26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1470-2045(14)71156-8","article-title":"Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial","volume":"16","author":"Bartelink","year":"2015","journal-title":"Lancet Oncol"},{"issue":"30","key":"10.1016\/j.esmoop.2023.101206_bib27","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1200\/JCO.2008.21.5764","article-title":"Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial","volume":"27","author":"Jones","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101206_bib28","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.1997.15.3.963","article-title":"Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France","volume":"15","author":"Romestaing","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2023.101206_bib29","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00066-002-1053-1","article-title":"Electron and high-dose-rate brachytherapy boost in the conservative treatment of stage I-II breast cancer first results of the randomized Budapest boost trial","volume":"178","author":"Polgar","year":"2002","journal-title":"Strahlenther Onkol"},{"issue":"36","key":"10.1016\/j.esmoop.2023.101206_bib30","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.1200\/JCO.2013.49.7842","article-title":"Randomized controlled trial of intensity-modulated radiotherapy for early breast cancer: 5-year results confirm superior overall cosmesis","volume":"31","author":"Mukesh","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101206_bib31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.radonc.2009.03.003","article-title":"A\u00a0randomised controlled trial of forward-planned radiotherapy (IMRT) for early breast cancer: baseline characteristics and dosimetry results","volume":"92","author":"Barnett","year":"2009","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101206_bib32","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.radonc.2006.12.008","article-title":"Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy","volume":"82","author":"Donovan","year":"2007","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101206_bib33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.radonc.2011.06.026","article-title":"First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE\/04\/015)","volume":"100","author":"Agrawal","year":"2011","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101206_bib34","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ijrobp.2010.11.025","article-title":"Radiotherapy breast boost with reduced whole-breast dose is associated with improved cosmesis: the results of a comprehensive assessment from the St. George and Wollongong randomized breast boost trial","volume":"82","author":"Hau","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101206_bib35","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.radonc.2013.08.040","article-title":"Hypofractionated whole breast irradiation for patients with large breasts: a randomized trial comparing prone and supine positions","volume":"108","author":"Mulliez","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.esmoop.2023.101206_bib36","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1748-717X-7-80","article-title":"Short course radiotherapy with simultaneous integrated boost for stage I-II breast cancer, early toxicities of a randomized clinical trial","volume":"7","author":"van Parijs","year":"2012","journal-title":"Radiat Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2023.101206_bib37","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1001\/jamaoncol.2015.2666","article-title":"Acute and short-term toxic effects of conventionally fractionated vs hypofractionated whole-breast irradiation: a randomized clinical trial","volume":"1","author":"Shaitelman","year":"2015","journal-title":"JAMA Oncol"},{"issue":"13","key":"10.1016\/j.esmoop.2023.101206_bib38","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2007.15.2488","article-title":"A\u00a0multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis","volume":"26","author":"Pignol","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101206_bib39","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.radonc.2013.04.021","article-title":"The UK HeartSpare Study: randomised evaluation of voluntary deep-inspiratory breath-hold in women undergoing breast radiotherapy","volume":"108","author":"Bartlett","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.esmoop.2023.101206_bib40","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1200\/JCO.21.02831","article-title":"Intensity-modulated radiation therapy reduces patient-reported chronic toxicity compared with conventional pelvic radiation therapy: updated results of a phase III trial","volume":"40","author":"Yeung","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101206_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100362","article-title":"Prioritising systemic cancer therapies applying ESMO\u2019s tools and other resources to assist in improving cancer care globally: the Kazakh experience","volume":"7","author":"Latino","year":"2022","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101206_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100166","article-title":"Twelve years of European cancer drug approval-a systematic investigation of the \u2018magnitude of clinical benefit\u2019","volume":"6","author":"Grossmann","year":"2021","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101206_bib43","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ijrobp.2006.06.013","article-title":"Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial","volume":"66","author":"Pow","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101206_bib44","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1470-2045(10)70290-4","article-title":"Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial","volume":"12","author":"Nutting","year":"2011","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101206_bib45","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2016.69.1378","article-title":"Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial","volume":"35","author":"Chun","year":"2017","journal-title":"J\u00a0Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923004301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923004301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:30:07Z","timestamp":1761856207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702923004301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2059702923004301"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101206","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for adjuvant radiotherapy in breast cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101206","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101206"}}